RecruitMe Clinical Trial

A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma
A study patients with metastatic or recurrent Gastric or Gastroesophageal Junction Adencarcinoma using study drug MEDI4736
Sponsor:MedImmune
Enrolling:Male and Female Patients
Age Range:Between 18 and 95 years old
IRB Number:AAAO8258
U.S. Government ID:NCT02340975
Contact: Vulaj Victoria: 646 317 6085 / po2178@columbia.edu
Additional Study Information:

This study is being conducted in participants with gastric (stomach) cancer or cancer of the astroesophageal junction (where the esophagus meets the stomach) that has returned after treatment (recurrent), or has spread to another area of your body (metastatic). The main purpose is to determine the doses and dosing schedule of both MEDI4736 and tremelimumab that are safe and tolerable when given together in subjects with gastric (stomach) cancer or cancer of the gastroesophageal junction (where the esophagus meets the stomach). In the second part of this study, adult subjects with metastatic or recurrent gastric cancer or cancer of the gastroesophageal junction will be randomly enrolled into 1 of 4 treatment groups based on previously received treatments for their cancer

This study is closed
Investigator
Gulam Manji, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Vulaj Victoria
Email: po2178@columbia.edu
Phone: 646 317 6085